💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cinacalcet

CHEMBL1201284 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
357.4 g/mol
LogP
6.1
Phase
4

A calcimimetic agent that increases the sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. It is used to treat secondary hyperparathyroidism in dialysis patients and hypercalcemia in parathyroid carcinoma. Hypocalcemia is an important adverse effect that requires monitoring of serum calcium levels.

आणविक भार

357.4000 g/mol

LogP

6.10

TPSA

12.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

Osteoporosis Chronic Kidney Disease Nephrology Cardiovascular Disease Prostate Cancer

क्रिया का तंत्र

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H22F3N

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
घूर्णनीय बंधन

                        
6

                    

                    
                    
                    

                        
भारी परमाणु

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A calcimimetic agent that increases the sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. It is used to treat secondary hyperparathyroidism in dialysis patients and hypercalcemia in parathyroid carcinoma. Hypocalcemia is an important adverse effect that requires monitoring of serum calcium levels.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cinacalcet is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201284.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 156419.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.